BioCentury
ARTICLE | Company News

Clino, Astellas deal

February 8, 2016 8:00 AM UTC

Clino granted Astellas worldwide rights to develop and commercialize adeno-associated virus (AAV)-modified Volvox channelrhodopsin-1 (ChR1) to treat retinitis pigmentosa. The product is an engineered...